Molecular Neurodegeneration
Open Access
Journal formatting to fit the target journal guidelines
Experts ensure all elements of your paper match journal formatting guidelines to improve publication success rate!
Aims and Scope
Molecular Neurodegeneration is a peer-reviewed scientific journal covering research on the molecular mechanisms underlying neurodegeneration, especially as pertaining to neurodegenerative diseases. The journal was established in 2006 and is published by BioMed Central. The editors-in-chief are Guojun Bu (Mayo Clinic) and Huaxi Xu (Sanford-Burnham Medical Research Institute). It is the official journal of the BrightFocus Foundation. Less
Key Metrics
View Chart Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
- PublisherBMC
- LanguageEnglish
- FrequencyContinuous publication
- Article Processing ChargesEUR 2590 | USD 2990 | GBP 2090
- Publication Time12
- Editorial Review ProcessAnonymous peer review
- LanguageEnglish
- Society/Institute/SponsorBrightFocus Foundation
- FrequencyContinuous publication
- Publication Start Year2006
- Publisher URL
- Website URL
- Plagiarism
- Publication Time12
- Waiver Policy
- Editorial Team
- Review ProcessAnonymous peer review
- Review Url
- Author instructions
- Copyright Details
- Deposit PolicySherpa/Romeo
- License typeCC BY, CC0
- OA statement
Ready to spotlight your research findings?
Impress peers and journals alike with a concise, visual summary of your work.
Meets Top Publisher Standards: Essential for leading journals like Elsevier.Enhances Engagement: Research papers with graphical abstracts receive 3X more downloads and 8X more shares.Tailored Just for You: We’ll create a custom graphical abstract based on your manuscript—no sketches needed.
3000+ graphical abstracts produced with 4.8/5 customer rating | Months | % Papers published |
|---|---|
| 0-3 | 5% |
| 4-6 | 32% |
| 7-9 | 48% |
| >9 | 14% |
Topics Covered
Year-wise Publication
- 5Y
- 10Y
FAQs
Since when has Molecular Neurodegeneration been publishing? 
The Molecular Neurodegeneration has been publishing since 2006 till date.
How frequently is the Molecular Neurodegeneration published?
Molecular Neurodegeneration is published Continuous publication.
Who is the publisher of Molecular Neurodegeneration?
The publisher of Molecular Neurodegeneration is BMC.
Where can I find a journal's aims and scope of Molecular Neurodegeneration?
For the Molecular Neurodegeneration's Aims and Scope, please refer to the section above on the page.
How can I view the journal metrics of Molecular Neurodegeneration on editage?
For the Molecular Neurodegeneration metrics, please refer to the section above on the page.
What is the eISSN and pISSN number of Molecular Neurodegeneration?
The eISSN number is 1750-1326 and pISSN number is 1750-1326 for Molecular Neurodegeneration.
What is the focus of this journal?
The journal covers a wide range of topics inlcuding Parkinson's disease, Binding properties, Cerebrospinal fluid, Hippocampus, Alzheimer's disease, Mutant, Nootropic, Extracellular vesicles, Dementia, Glaucoma, Clusterin, Mass spectrometry, Microglia, Volatile fatty acids, Medial frontal gyrus, Frontotemporal lobar degeneration, Autophagy, Cognitive impairment, Oxidative stress, Cerebral cortex.
Why is it important to find the right journal for my research?
Choosing the right journal ensures that your research reaches the most relevant audience, thereby maximizing its scholarly impact and contribution to the field.
Can the choice of journal affect my academic career?
Absolutely. Publishing in reputable journals can enhance your academic profile, making you more competitive for grants, tenure, and other professional opportunities.
Is it advisable to target high-impact journals only?
While high-impact journals offer greater visibility, they are often highly competitive. It's essential to balance the journal's impact factor with the likelihood of your work being accepted.